Targeting Type 2 and Non-type 2 Asthma: Emerging Biologics and Personalized Strategies.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing existing literature without systematic review methodology or new human data.
PubMed 42223828 · doi:10.1007/s11882-026-01283-4
What was done
This review summarized current biologic therapies, emerging targeted interventions, and management challenges for Type 2 (eosinophilic) and Type 1/non-Type 2 (neutrophilic, steroid-resistant) asthma phenotypes based on existing literature.
What was found
The abstract reports no quantitative results, sample sizes, or effect estimates. It qualitatively describes anti-IgE, anti-IL-5, anti-IL-4/IL-13, and anti-TSLP biologics as effective in controlling severe eosinophilic asthma. For Type 1 and mixed phenotypes, emerging approaches include anti-TNF-alpha, CXCR2 antagonists, IL-17 blockers, JAK-STAT inhibitors, microbiome interventions, and bispecific antibodies, alongside ongoing challenges regarding cost, access, biomarker availability, and immunosuppression risks.
Why it matters
The paper highlights the therapeutic gap between well-served Type 2 asthma and poorly addressed non-Type 2 or steroid-resistant endotypes, outlining the need for biomarker-driven personalized strategies.
Limits
As a narrative review, the work introduces no original empirical data, quantitative comparisons, or formal systematic search and meta-analysis methods. Specific treatment efficacy rates, safety outcomes, and patient cohort details are not reported in the abstract.